EFFECTIVENESS OF VISCOSUPPLEMENTATION IN THE TREATMENT OF HEMOPHILIC ARTHROPATHY: A SYSTEMATIC REVIEW.

Authors:
Martins SCM; DE Andrade E; Silva MBE; Ozelo MC; Campos GC and 1 more

Journal:
Acta Ortop Bras

Publication Year: 2023

DOI:
10.1590/1413-785220233105e271857

PMCID:
PMC10726718

PMID:
38115879

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Acta Ortop Bras

Abbreviation: Acta Ortop Bras

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Orthopedics

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
AGREEMENT ON MRI DIAGNOSIS IN COMPRESSIVE MALIGNANT VERTEBRAL FRACTURES.
Dos Santos IMG; Herrero CFPDS; Pratali RR and 3 more (2023) - Transparency Score: 3/6
ANKLE ARTHRODESIS WITH INTRAMEDULLARY RETROGRADE NAIL FOR BONE TUMORS. PRELIMINARY RESULTS AND SURG…
Casanova JM; Freitas JP; Fonseca RL and 2 more (2023) - Transparency Score: 2/6
ANTEROMEDIAL OR CENTRAL ANATOMIC ACL RECONSTRUCTION? A CADAVERIC HIP-TO-TOE STUDY.
Fernandes TL; Souza MO; Albuquerque C and 3 more (2023) - Transparency Score: 3/6
COMBINED PLATE VERSUS EXTERNAL FIXATION FOR DISTAL RADIUS FRACTURES.
Polat O; Toy S; Özbay H. (2023) - Transparency Score: 2/6
COMPLICATIONS AFTER SURGICAL TREATMENT OF JUPITER'S MONTEGGIA TYPE II FRACTURES.
Guerra ER; Araújo Filho LRS; Kikuta FK and 3 more (2023) - Transparency Score: 2/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"MCO has received grants from BioMarin, Novo Nordisk, Pfizer, Sanofi, Roche, and Takeda, and has participated as speaker and/or in advisory boards sponsored by Bayer, BioMarin, Novo Nordisk, Pfizer, Roche, and Takeda. SCMM, EJA, MBS, GCC and RGP declare no potential conflict of interest related to this article."

Evidence found in paper:

"MCO has received grants from BioMarin, Novo Nordisk, Pfizer, Sanofi, Roche, and Takeda, and has participated as speaker and/or in advisory boards sponsored by Bayer, BioMarin, Novo Nordisk, Pfizer, Roche, and Takeda. SCMM, EJA, MBS, GCC and RGP declare no potential conflict of interest related to this article."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025